Keros Therapeutics Inc. Stock News

Keros Therapeutics, Inc. (“Keros”) (KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from he

A sense of cautious optimism is looming over the Street given the progress in the reopening of the U.S. economy, and while the recent uptick isn’t necessarily indicative of a full recovery, it’s c

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29)• Arvinas Inc (NASDAQ: ARVN) • Biondvax Pharmaceu

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) * AstraZeneca plc (NYSE: AZN) * Alnylam Pharmaceuti

Kerr Mines Inc. (TSX:KER) announces its plans for the first phase of its 2020 resource and reserve expansion program at the Copperstone Mine

These companies just raised significant cash to advance promising drug pipelines.

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Ar

Company also exceeds offering target Continue reading...

Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO, Stocks: KROS,XLRN,TSE:4503,BMY,FGEN,SRRA,IMRA,ZNTL, release date:Apr 21, 2020

Details the CEO buys this past week for the following companies: Ryman Hospitality Properties, OPKO Health, Keros Therapeutics and Spirit Realty Capital Continue reading...

Weekly CEO Buys Highlight, Stocks: RHP,OPK,KROS,SRC, release date:Apr 19, 2020

Fly Insider: Gamestop, SharpSpring among week's notable insider trades NBIX GME BSET KWR KROS TGE SHSP WDAY MRVL PEN

Insider purchases tend to yield strong returns which makes it an interesting strategy to analyse. My thesis shows abnormal returns of 13.25% annually. Each week